Literature DB >> 7707325

Reductive chemistry of the novel hypoxia-selective cytotoxin 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide.

B D Palmer1, P van Zijl, W A Denny, W R Wilson.   

Abstract

5-[N,N-Bis(2-chloroethyl)amino]-2,4-dinitrobenzamide (1; SN 23862) is a novel bioreductive drug whose selective toxicity for hypoxic cells appears due to oxygen-inhibited enzymatic reduction of one of the nitro groups to the corresponding amine or hydroxylamine. Radiolytic reduction of 1 using up to four reducing equivalents in 1 N sodium formate was shown to proceed via electron addition to the 4-nitro group, thereby identifying this substituent as the most electron-affinic site in the molecule. The initially-formed 4-hydroxylamine and its N-hydroxytetrahydroquinoxaline half-mustard cyclization product (formed by intramolecular reaction with one arm of the adjacent mustard group) are reduced to the corresponding 4-amines upon further addition of electrons, although reduction of the 2-nitro group leading to 2,4-diamino products begins after addition of only six electron equivalents. Radiolytic reduction of the structurally similar 5-(aziridin-1-yl)-2,4-dinitrobenzamide (2; CB 1954) with six electron equivalents also occurs at the 4-nitro group to give the 4-hydroxylamine and 4-amine. The product mixture from reduction of 2 is less complex, largely because the corresponding 4-hydroxylamine and 4-amine are stable. The major reduction products of 1 were chemically synthesized by unequivocal routes to provide authentic samples for identification of the products of radiolytic reduction and to allow determination of their cytotoxicities. The 2- and 4-amino derivatives of 1 are significantly more cytotoxic than the parent drug, although the toxicity of the 4-amine is moderated by its facile conversion to the corresponding less toxic tetrahydroquinoxaline half-mustard. Although the 2- and 4-hydroxylamino derivatives were prepared by chemical reduction of 1, their toxicity could not be evaluated because of their instability. The 4-hydroxylamine reacts intramolecularly with the 5-mustard group somewhat more rapidly than does the 4-amine, while the 2-hydroxylamine is converted into a 2,2'-azoxy dimer following aerial oxidation to the 2-nitroso derivative. The fully reduced 2,4-diamino derivative of 1 is 10-fold more cytotoxic again than the 2-amine and, surprisingly, does not undergo spontaneous intramolecular alkylation. This elucidation of the reduction chemistry of 1 will facilitate further investigations of the toxic products generated from this compound both by hypoxic tumor cells and by ADEPT enzymes.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7707325     DOI: 10.1021/jm00007a019

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  8 in total

Review 1.  Recent developments in the design of bioreductive drugs.

Authors:  W A Denny; W R Wilson; M P Hay
Journal:  Br J Cancer Suppl       Date:  1996-07

2.  Tertiary amine N-oxides as bioreductive drugs: DACA N-oxide, nitracrine N-oxide and AQ4N.

Authors:  W R Wilson; W A Denny; S M Pullen; K M Thompson; A E Li; L H Patterson; H H Lee
Journal:  Br J Cancer Suppl       Date:  1996-07

3.  Nitroreductase-triggered activation of a novel caged fluorescent probe obtained from methylene blue.

Authors:  Jungeun Bae; Louis E McNamara; Manal A Nael; Fakhri Mahdi; Robert J Doerksen; Gene L Bidwell; Nathan I Hammer; Seongbong Jo
Journal:  Chem Commun (Camb)       Date:  2015-08-18       Impact factor: 6.222

4.  Bioreductive prodrug PR-104 improves the tumour distribution and titre of the nitroreductase-armed oncolytic adenovirus ONYX-411NTR leading to therapeutic benefit.

Authors:  Dean C Singleton; Alexandra M Mowday; Chris P Guise; Sophie P Syddall; Sally Y Bai; Dan Li; Amir Ashoorzadeh; Jeff B Smaill; William R Wilson; Adam V Patterson
Journal:  Cancer Gene Ther       Date:  2021-11-26       Impact factor: 5.854

5.  Prodrugs for Gene-Directed Enzyme-Prodrug Therapy (Suicide Gene Therapy).

Authors:  William A. Denny
Journal:  J Biomed Biotechnol       Date:  2003

6.  Hypoxia imaging in cells and tumor tissues using a highly selective fluorescent nitroreductase probe.

Authors:  Dan Yang; Hang Yu Tian; Tie Nan Zang; Ming Li; Ying Zhou; Jun Feng Zhang
Journal:  Sci Rep       Date:  2017-08-23       Impact factor: 4.379

7.  2-Amino metabolites are key mediators of CB 1954 and SN 23862 bystander effects in nitroreductase GDEPT.

Authors:  N A Helsby; D M Ferry; A V Patterson; S M Pullen; W R Wilson
Journal:  Br J Cancer       Date:  2004-03-08       Impact factor: 7.640

8.  Restoring Tumour Selectivity of the Bioreductive Prodrug PR-104 by Developing an Analogue Resistant to Aerobic Metabolism by Human Aldo-Keto Reductase 1C3.

Authors:  Maria R Abbattista; Amir Ashoorzadeh; Christopher P Guise; Alexandra M Mowday; Rituparna Mittra; Shevan Silva; Kevin O Hicks; Matthew R Bull; Victoria Jackson-Patel; Xiaojing Lin; Gareth A Prosser; Neil K Lambie; Gabi U Dachs; David F Ackerley; Jeff B Smaill; Adam V Patterson
Journal:  Pharmaceuticals (Basel)       Date:  2021-11-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.